- Home
- UG vs ALGS Comparison
UG vs ALGS Comparison
Compare UG & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UG | ALGS |
|---|---|---|
| Founded | 1942 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 34.6M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UG | ALGS |
|---|---|---|
| Price | $7.38 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 9.3K | ★ 105.2K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $10,545,468.00 | $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | $36.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.58 | $3.98 |
| 52 Week High | $8.78 | $13.69 |
Technical Indicators
Market Signals| Indicator | UG | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 56.92 |
| Support Level | $6.90 | $4.80 |
| Resistance Level | $7.49 | $5.94 |
| Average True Range (ATR) | 0.37 | 0.50 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 21.10 | 84.07 |
Price Performance
Historical ComparisonAbout UG United-Guardian Inc.
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.